| First Author | Zhang H | Year | 2022 |
| Journal | J Exp Med | Volume | 219 |
| Issue | 5 | PubMed ID | 35333296 |
| Mgi Jnum | J:331099 | Mgi Id | MGI:7384228 |
| Doi | 10.1084/jem.20211828 | Citation | Zhang H, et al. (2022) AMFR drives allergic asthma development by promoting alveolar macrophage-derived GM-CSF production. J Exp Med 219(5):e20211828 |
| abstractText | Alveolar macrophages (AMs) are specialized tissue-resident macrophages that orchestrate the immune response in allergic inflammation and asthma. However, what signals direct AMs to cross talk with other immune cells remains unclear. Here, we report that autocrine motility factor receptor (AMFR), an endoplasmic reticulum-resident E3 ubiquitin ligase, is upregulated in AMs of asthma and is critical for this condition. AMFR deficiency significantly decreased allergy-induced T helper 2 (Th2) and eosinophilic inflammation, with less granulocyte-macrophage colony-stimulating factor (GM-CSF) production in AMs. Mechanistically, following thymic stromal lymphopoietin (TSLP) stimulation, AMFR associated directly with cytokine-inducible SH2-containing protein (CIS), induced the ubiquitination of Lys48-linked polyubiquitination of CIS, and consequently blocked the inhibitory effect of CIS on signal transducer and activator of transcription 5 (STAT5) phosphorylation and the downstream pathway activation in AMs. In conclusion, our results demonstrate that AMFR serves a crucial role in promoting inflammation in asthma through regulating AM function, and may emerge as a new potential drug target for asthma therapy. |
